Latest News

In October 2023, the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) honored Carolyn Rochester, MD, FCCP, professor of medicine, with the prestigious Thomas L. Petty Distinguished Pulmonary Scholar Award. The award is presented to an individual “who has made significant advances in the field of pulmonary rehabilitation through research and scholarly contributions and has earned national prominence in the field.”

The new Yale Bronchiectasis and NTM Infections Program at the Winchester Center for Lung Disease specializes in treating patients with chronic respiratory tract infections, including one caused by nontuberculous mycobacteria.

The Winchester Center for Lung Disease (WCLD) opened in March 2021 at the North Haven Medical Center to improve access to exceptional care for more people with lung conditions. The expanded facilities at the Winchester Center have allowed expansion of subspecialized pulmonary care as well as access to a wide array of multidisciplinary services, more than what was possible at the original Winchester Chest Clinic (WCC) on Yale New Haven Hospital’s York Street Campus.

The Yale Interventional Pulmonary team in Yale’s Section of Pulmonary, Critical Care, and Sleep Medicine (Yale-PCCSM) employs advanced technologies to diagnose and treat diseases in the chest, such as lung nodules and masses, lymph node enlargement, complex airways, and pleural effusions. The program, led by Kyle Bramley, MD, assistant professor of medicine (pulmonary), was one of the first interventional pulmonology programs in Connecticut when it was established in 2009. Today it remains the largest interventional pulmonary service in the state.

Older adults who survive a critical illness, such as sepsis or respiratory failure, often have symptoms that restrict activities, but little is known about how these symptoms change over time or compare with those prior to illness, and whether these changes differ among vulnerable subgroups. In a new study, Yale researchers evaluated changes in restricting symptoms among adults aged 70 or older during the six months after discharge from the ICU or intensive care unit.

Yale scientists are evaluating a new method to treat debilitating and deadly pulmonary fibrosis.

Six Ukrainian doctors are getting advanced training at Yale as part of a program organized by Doctors United for Ukraine (DU4U), a nonprofit incorporation of Yale School of Medicine and Yale School of Public Health faculty and staff that supports Ukrainian doctors and health care organizations during the Russian war.

A team led by Naftali Kaminski, MD, used a newly designed molecule, called MRG-229, with potential therapeutic implications for idiopathic pulmonary fibrosis. The study is one of the first to use a microRNA mimic as a viable therapeutic in the lungs.

Naftali Kaminski, MD, was honored by the American Thoracic Society as the J. Burns Amberson Lecturer, an award that recognizes a career of major lifetime contributions.